TickerFacts.

Volitionrx Ltd (VNRX): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2012-12-31, 2016-12-31, 2017-12-31, 2021-12-31, 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$10.08M
Year ended 2025-12-31
$9.41M
Trailing 12 months to 2026-06-30
-13.0%
3-year compound annual growth
$19.55M2011-12-31: $1.52M2012-12-31: $2.77M2013-12-31: $2.50M2014-12-31: $4.04M2015-12-31: $6.10M2016-12-31: $7.90M2017-12-31: $8.03M2018-12-31: $10.91M2019-12-31: $10.36M2020-12-31: $14.53M2021-12-31: $13.02M2022-12-31: $15.33M2023-12-31: $19.55M2024-12-31: $14.41M2025-12-31: $10.08M$10.08M
2011-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$10.08M-30.0%2026-03-31, From 2025-01-01
2024-12-31$14.41M-26.3%2026-03-31, From 2024-01-01
2023-12-31$19.55M+27.5%2025-03-31, From 2023-01-01
2022-12-31$15.33Mn/c2024-03-25, From 2022-01-01
2021-12-31$13.02Mn/c2023-03-15, From 2021-01-01
2020-12-31$14.53M+40.2%2022-03-30, From 2020-01-01
2019-12-31$10.36M-5.0%2021-03-22, From 2019-01-01
2018-12-31$10.91M+35.9%2020-02-20, From 2018-01-01
2017-12-31$8.03Mn/c2019-03-13, From 2017-01-01
2016-12-31$7.90Mn/c2018-03-01, From 2016-01-01
2015-12-31$6.10M+50.9%2017-03-10, From 2015-01-01
2014-12-31$4.04M+61.5%2016-03-11, From 2014-01-01
2013-12-31$2.50M-9.7%2015-03-18, From 2013-01-01
2012-12-31$2.77Mn/c2014-03-28, From 2012-01-01
2011-12-31$1.52Mn/a2013-04-01, From 2011-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Volitionrx Ltd (VNRX)2025-12-31$10.08M-30.0%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$245.07M+49.8%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$15.90M+61.6%
Biomerica Inc (BMRA)2026-05-31$788.0K-23.0%
Anbio Biotechnology (NNNN)2025-12-31$201.3K-55.7%
Aspira Women's Health Inc. (AWHL)2025-12-31$2.88M-11.9%
Immucell Corp (ICCC)2025-12-31$3.04M-22.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$2.20M-20.4%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$388.86M-16.6%

Compare VNRX, CLDX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗